 Moreover, for at least two indications or approaches this may be a secondary issue.Where the therapeutic approach (e.g., in analgesia) is agonist-mediated desensitization then the hyperthermic effects of effects of antagonists may not be relevant.Secondarily in applications such as TRPV1 antagonism for the treatment of severe conditions such as heart failure, then there may be an acceptable trade-off with mild hyperthermia, although no hyperthermia was observed in rodent models of heart failure treated with BCTC, SB366791 or AMG9810.